Loading…
Cocrystal Pharma, Inc. is projected to decline to $0.9106 by 2027, a -3% move from its current price of $0.94. COCP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.9161 | $0.9395 | $0.9636 | -0.05% |
| Aug 6 | $0.9061 | $0.9391 | $0.9733 | -0.10% |
| Aug 7 | $0.8984 | $0.9386 | $0.9807 | -0.15% |
| Aug 8 | $0.8919 | $0.9382 | $0.9869 | -0.20% |
| Aug 9 | $0.8861 | $0.9377 | $0.9923 | -0.24% |
| Aug 10 | $0.8809 | $0.9372 | $0.9972 | -0.29% |
| Aug 11 | $0.8761 | $0.9368 | $1.00 | -0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8761 | $0.9368 | $1.00 | -0.34% |
| Week 2 | $0.8493 | $0.9336 | $1.03 | -0.68% |
| Week 3 | $0.8286 | $0.9304 | $1.04 | -1.02% |
| Week 4 | $0.8111 | $0.9272 | $1.06 | -1.36% |
| Week 5 | $0.7956 | $0.9241 | $1.07 | -1.70% |
| Week 6 | $0.7817 | $0.9209 | $1.08 | -2.03% |
| Week 7 | $0.7688 | $0.9178 | $1.10 | -2.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cocrystal Pharma, Inc. is a biotechnology company focused on discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV).
It develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV.
The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc.
was headquartered in Bothell, Washington.
COCP is the stock symbol for Cocrystal Pharma, Inc. and is currently trading at $0.82 with a market capitalization of $11.31M, ranking 5051. The price action is framed by a forecast that projects near-term flatness and longer-term upside, with multiple years showing meaningful gains.
The 30-day technical picture shows a tight price band around a near-term support/resistance setup, while the annualized volatility stands at 50%, underscoring the risk associated with the name. The 30-day range runs from $0.6941 to $0.9688, and the near-term price trajectory is informed by a price forecast that includes gradual appreciation toward the 2030s and beyond, with notable upside potential in later years.
Over the multi-year horizon, the forecast yields a path where the average price climbs from the low- to mid-$0.82 range in the mid-2020s to higher targets in the 2030s, 2040s, and 2050s, with long-run bullish sentiment and sizable max upside indicated in the 2040s and 2050s.
A major floor 29.8% below — a decisive break under it would weaken the trend.
The nearest floor, 12.8% below — buyers have tended to step in here.
The nearest ceiling, 12.8% above — a clean break opens room to run.
A major ceiling 67.0% above — clearing it would confirm fresh momentum.
Key COCP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COCP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.882 | Buy | $0.8695 | Buy |
| MA 10 | $0.903 | Buy | $0.897 | Buy |
| MA 20 | $0.9425 | Sell | $0.9328 | Buy |
| MA 50 | $1.00 | Sell | $1.01 | Sell |
| MA 100 | $1.14 | Sell | $1.07 | Sell |
| MA 200 | $1.09 | Sell | $1.15 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 26.30 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -205.45 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -14.58 | Sell |
| Bollinger %B (20,2) | -0.08 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.53 | Sell |
| Awesome (5,34) | -0.09 | Sell |
| Ultimate (7,14,28) | 20.96 | Buy |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 0.85 | Buy |
| ADX (14) | 26.93 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture for COCP is NEUTRAL. The RSI14 sits at 30, suggesting limited near-term momentum, while the 50-day simple moving average is $1.00 and the 200-day simple moving average is $1.09, providing a rough upper bound against recent drift.
In the near term, support is identified at $0.82 and resistance at $1.06, creating a defined trading range around current levels. The 30-day price range spans from $0.6941 to $0.9688, illustrating the recent limitations in upside movement and the potential for volatility to reemerge.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.82 | $0.94 | $1.13 | 0% | Neutral | |
| $0.7312 | $0.9106 | $1.20 | -3% | Neutral | |
| $0.763 | $0.9752 | $1.33 | +4% | Neutral | |
| $0.7159 | $0.9348 | $1.31 | -1% | Neutral | |
| $0.829 | $1.10 | $1.58 | +17% | Neutral | |
| $0.9483 | $1.28 | $1.87 | +37% | Bullish | |
| $0.9126 | $1.25 | $1.87 | +34% | Bullish | |
| $0.9165 | $1.28 | $1.93 | +36% | Bullish | |
| $0.9013 | $1.28 | $1.96 | +36% | Bullish | |
| $0.8966 | $1.29 | $2.00 | +37% | Bullish | |
| $1.22 | $1.85 | $3.06 | +97% | Bullish | |
| $1.75 | $2.96 | $5.31 | +215% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.82 | $0.94 | $1.11 | +0.00% |
| September 2026 | $0.7559 | $0.8918 | $1.08 | -5.12% |
| October 2026 | $0.7572 | $0.899 | $1.10 | +0.81% |
| November 2026 | $0.7699 | $0.9189 | $1.13 | +2.21% |
| December 2026 | $0.7572 | $0.9081 | $1.13 | -1.17% |
Click any year to see its month-by-month COCP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cocrystal Pharma, Inc.'s 2026 outlook centres on $0.94, within a $0.82 to $1.13 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, COCP could reach as high as $1.20, with a base case around $0.9106 and support toward $0.7312 — roughly -3% from $0.94. A consolidation phase looks the most probable path here.
Expect COCP to range from $0.763 to $1.33 through 2028. The $0.9752 average target implies a +4% move from current prices. That is up +7% on the projected 2027 average. Price action looks broadly range-bound.
The COCP price prediction for 2029 points to an average of $0.9348 (low $0.7159, high $1.31) — a potential decline of -1% on today's $0.94. A consolidation phase looks the most probable path here.
In 2030, COCP is projected to trade between $0.829 and $1.58, averaging $1.10 — a potential gain of +17% from today's $0.94. That is up +18% on the projected 2029 average. Price action looks broadly range-bound.
Cocrystal Pharma, Inc.'s 2031 outlook centres on $1.28, within a $0.9483 to $1.87 range. That is up +16% on the projected 2030 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, COCP could reach as high as $1.87, with a base case around $1.25 and support toward $0.9126 — roughly +34% from $0.94. Momentum favours further upside here.
Expect COCP to range from $0.9165 to $1.93 through 2033. The $1.28 average target implies a +36% move from current prices. That is up +2% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The COCP price prediction for 2034 points to an average of $1.28 (low $0.9013, high $1.96) — a potential gain of +36% on today's $0.94. Momentum favours further upside here.
In 2035, COCP is projected to trade between $0.8966 and $2.00, averaging $1.29 — a potential gain of +37% from today's $0.94. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Cocrystal Pharma, Inc.'s 2040 outlook centres on $1.85, within a $1.22 to $3.06 range. That is up +44% on the projected 2035 average. That marks a +97% change versus current levels. Momentum favours further upside here.
By 2050, COCP could reach as high as $5.31, with a base case around $2.96 and support toward $1.75 — roughly +215% from $0.94. Buyers look set to stay in control over this stretch.
Investing $1,000 in COCP today (≈ 1,063.829787 COCP) could be worth
$3,145.98
+$2,145.98 (+215%) by 2050 · US Dollar
Based on the average projected COCP price of $2.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COCPwould be worth at today's price.
$1,000 invested in COCP on Jul 31, 2025 (≈ 578.034676 COCP) would be worth
$543.35
-$456.65 (-45.7%) today · 0.54× · US Dollar
Based on a COCP entry price of $1.73 vs. today's $0.94.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.9 | $1,044.44 | +4.4% |
| 1 month ago | $1.05 | $895.24 | -10.5% |
| 3 months ago | $1.38 | $681.16 | -31.9% |
| 6 months ago | $0.98 | $959.18 | -4.1% |
| 1 year ago | $1.73 | $543.35 | -45.7% |
| All time (5.0y) ago | $12.96 | $72.53 | -92.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COCP forecast.
Our base-case forecast reaches $1.90 around 2050.
Implied market cap at $1.90: $26.2M
The multi-year forecast shows a clear progression from a near-term flat-to-mildly-positive environment to a longer-run bullish regime. In 2026, the min/avg/max are $0.82, $0.82, and $0.984, with a 0% ROI, followed by 2027’s min/avg/max of $0.6385, $0.7951, and $1.04 with a -3% ROI. 2028 offers a modest uptick to an avg of $0.8513 and a max of $1.16 (3.8% ROI), while 2029 prints an avg of $0.8151 with a max of $1.14 and a -0.6% ROI.
From 2030 onward, the forecast shows stronger upside: 2030 min $0.7248, avg $0.9645, max $1.38 (ROI 17.6%), sentiment NEUTRAL; 2031 min $0.8292, avg $1.12, max $1.64 (ROI 36.9%), sentiment BULLISH; 2032 min $0.7964, avg $1.10, max $1.63 (ROI 33.6%), sentiment BULLISH; 2033 min $0.8012, avg $1.12, max $1.69 (ROI 36.4%), sentiment BULLISH; 2034 min $0.7881, avg $1.12, max $1.71 (ROI 36%), sentiment BULLISH; 2035 min $0.7827, avg $1.12, max $1.75 (ROI 37%), sentiment BULLISH.
Looking further out, 2040 shows a stronger path with min $1.06, avg $1.62, max $2.67 (ROI 97.7%), sentiment BULLISH; and 2050 reaches min $1.53, avg $2.59, max $4.65 (ROI 215.4%), sentiment BULLISH. The long-run trend carries higher upside potential but retains notable risk and volatility in the nearer terms, as reflected by the 50% annualized volatility.
Tap a question to reveal the answer.
In 2030, the forecast shows an avg price of $0.9645 with a min of $0.7248 and a max of $1.38; ROI 17.6%. Sentiment is NEUTRAL.
The near term shows limited upside in 2026 (avg $0.82; ROI 0%) and a negative ROI in 2027 (-3%) and 2029 (-0.6%), but long-run upside is indicated with higher avg prices and positive ROIs in 2030 onward (e.g., 2031 ROI 36.9%, 2040 ROI 97.7%, 2050 ROI 215.4%).
The 2040 forecast shows a max price of $2.67 with an average of $1.62, indicating that a $2 target is within the projected upside—though actual results may differ.
Current price is $0.82 and market cap is $11.31M.
RSI14 is 30, indicating neutral momentum. The SMA50 is $1.00 and the SMA200 is $1.09. Support is $0.82 and resistance is $1.06, with the 30-day range between $0.6941 and $0.9688.
Cocrystal Pharma, Inc. Community Discussion
0Share your Cocrystal Pharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.